A multicentre, observational, prospective study of the current practice in major centres in Australia and New Zealand for achieving haemostasis in consecutive patients who present with significant haemorrhage, thromboembolism or urgent surgery whilst on new or established oral anticoagulants

Not Applicable

Recruiting

• Conditions: Significant haemorrhage; Thromboembolism; Urgent surgery; Blood - Other blood disorders

• Registration Number: ACTRN12613001304729
• Lead Sponsor: ARES Collaborative

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-11-22
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

Patients presenting with significant haemorrhage, thromboembolism or require anticoagulation reversal for urgent surgery and/or a procedure and have taken a NOAC (dabigatran, rivaroxaban, or apixaban) or warfarin within the last 7 days.

Exclusion Criteria

Patients who have minor haemorrhage responding to local measures not requiring admission, blood testing or change in anticoagulant management.

Patients who are unable to have objective testing for recurrence of thromboembolism.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To observe the current practice for achieving haemostasis in 2000 patients who present with significant haemorrhage or urgent surgery whilst on new (dabigatran, rivaroxaban, apixaban or endoxaban) or established (warfarin) oral anticoagulants. Data will be collected by reviewing patients’ medical records.[42 months]

Secondary Outcome Measures

Name	Time	Method
In patients whilst on oral anticoagulants who present with embolism, determine the circumstances and level of anticoagulation at the time of presentation. Data will be collected by reviewing patients’ medical records.[42 months]